title: Improvement of renal function with selective thromboxane antagonism in lupus nephritis.
abstract: To test the hypothesis that the vasoconstrictor thromboxane A2 may affect renal hemodynamics in lupus nephritis, we examined the short-term effects of a selective thromboxane-receptor antagonist, BM 13,177, and of low-dose aspirin. In a randomized, double-blind, crossover study, 10 patients with biopsy-proved lupus nephritis were given a 48-hour continuous infusion of BM 13,177 or placebo. At base line, seven patients had markedly elevated urinary levels of thromboxane B2, the breakdown product of thromboxane A2. During the infusion of BM 13,177, the inulin clearance rate, which was 68 ml per minute per 1.73 m2 of body-surface area at base line, increased by an average of 24 percent (range, 12 to 47 percent; P less than 0.01). Para-aminohippurate clearance was increased to the same extent, with no change in the filtration fraction. The bleeding time doubled, indicating an occupancy of platelet thromboxane receptors of more than 95 percent. The hemodynamic changes were associated with a significant increase in sodium excretion from 76 to 118 mmol per day (P less than 0.01) but with no change in arterial blood pressure. In another study, 10 additional patients with lupus nephritis were randomly assigned to receive either placebo or 20 mg of aspirin twice daily for four weeks. The aspirin regimen produced a selective, cumulative inhibition of platelet cyclooxygenase activity and a doubling of bleeding time. However, there was no change in the inulin clearance rate and no change in urinary levels of thromboxane B2 or 6-keto-prostaglandin F1 alpha, which are indicators of renal synthesis of thromboxane A2 and prostacyclin, respectively. We conclude that in lupus nephritis, impairment of renal function is at least in part mediated hemodynamically and is reversible with a thromboxane antagonist. Platelets, however, are not a major source of thromboxane A2 synthesis and action within the kidney.
authors.affiliation: Department of Medicine, University of Rome La Sapienza, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Pierucci
authors.forename: B M
authors.initials: BM
authors.lastname: Simonetti
authors.forename: G
authors.initials: G
authors.lastname: Pecci
authors.forename: G
authors.initials: G
authors.lastname: Mavrikakis
authors.forename: S
authors.initials: S
authors.lastname: Feriozzi
authors.forename: G A
authors.initials: GA
authors.lastname: Cinotti
authors.forename: P
authors.initials: P
authors.lastname: Patrignani
authors.forename: G
authors.initials: G
authors.lastname: Ciabattoni
authors.forename: C
authors.initials: C
authors.lastname: Patrono
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012079:Renal Circulation / Q000187:drug effects; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors*
chemical_list: D013449:Sulfonamides; D013928:Thromboxane A2; C040624:sulotroban; D001241:Aspirin